Tumor necrosis predicts survival following neo-adjuvant chemotherapy for hepatoblastoma

Pediatric Blood and Cancer

Volumn 59, Issue 3, 2012, Pages 493-498

  Venkatramani, Rajkumar ^a   Wang, Larry ^a   Malvar, Jemily ^a   Dias, Dennis ^a   Sposto, Richard ^a,b   Malogolowkin, Marcio H ^a,b   Mascarenhas, Leo ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alpha fetoprotein; Chemotherapy; Hepatoblastoma; Necrosis; Platelet count; Surgery

Indexed keywords

ALPHA FETOPROTEIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEPATOBLASTOMA; HUMAN; HUMAN TISSUE; INFANT; LIVER HISTOLOGY; LIVER RESECTION; LIVER TRANSPLANTATION; MALE; NEWBORN; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; THROMBOCYTE COUNT; TREATMENT RESPONSE; TUMOR NECROSIS;

ALPHA-FETOPROTEINS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEPATOBLASTOMA; HUMANS; INFANT; INFANT, NEWBORN; LIVER NEOPLASMS; MALE; NECROSIS; NEOADJUVANT THERAPY; PROGNOSIS;

EID: 84863872152     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24038     Document Type: Article

References (22)

1. Stiller CA, Pritchard J, Steliarova-Foucher E. Liver cancer in European children: Incidence and survival, 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006; 42: 2115-2123.
2. Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A Report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol 2000; 18: 2665-2675.
3. Fuchs J, Rydzynski J, Von Schweinitz D, et al. Pretreatment prognostic factors and treatment results in children with hepatoblastoma. Cancer 2002; 95: 172-182.
4. Schnater JM, Aronson DC, Plaschkes J, et al. Surgical view of the treatment of patients with hepatoblastoma: Results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group. Cancer 2002; 94: 1111-1120.
5. Brown J, Perilongo G, Shafford E, et al. Pretreatment prognostic factors for children with hepatoblastoma-Results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer 2000; 36: 1418-1425.
6. Conran RM, Hitchcock CL, Waclawiw MA, et al. Hepatoblastoma: The prognostic significance of histologic type. Pediatr Pathol 1992; 12: 167-183.
7. Van Tornout J, Buckley J, Quinn J, et al. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: A report from the Children's Cancer Group. J Clin Oncol 1997; 15: 1190-1197.
8. von Schweinitz D, Hecker H, Schmidt-von-Arndt G, et al. Prognostic factors and staging systems in childhood hepatoblastoma. Int J Cancer 1997; 74: 593-599.
9. Lin PP, Jaffe N, Herzog CE, et al. Chemotherapy response is an important predictor of local recurrence in ewing sarcoma. Cancer 2007; 109: 603-611.
10. Gaynon PS, Bleyer WA, Steinherz PG, et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 1990; 18: 273-279.
11. Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: Results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 1998; 16: 2452-2458.
12. Wang LL, Filippi RZ, Zurakowski D, et al. Effects of neoadjuvant chemotherapy on hepatoblastoma: A morphologic and immunohistochemical study. Am J Surg Pathol 2010; 34: 287-299.
13. Saxena R, Leake JL, Shafford EA, et al. Chemotherapy effects on hepatoblastoma. A histological study. Am J Surg Pathol 1993; 17: 1266-1271.
14. Welch WJ. Construction of permutation tests. J Am Stat Assoc 1990; 85: 693-698.
15. Zsiros J, Maibach R, Shafford E, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: Final results of the SIOPEL-3HR study. J Clin Oncol 2010; 28: 2584-2590.
16. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998; 338: 1663-1671.
17. Marina N, Bielack S, Whelan J, et al. International collaboration is feasible in trials for rare conditions: The EURAMOS experience. Cancer Treat Res 2009; 152: 339-353.
18. Heifetz SA, French M, Correa M, et al. Hepatoblastoma: The Indiana experience with preoperative chemotherapy for inoperable tumors; clinicopathological considerations. Pediatr Pathol Lab Med 1997; 17: 857-874.
19. Haas JE, Muczynski KA, Krailo M, et al. Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. Cancer 1989; 64: 1082-1095.
20. Meyers RL, Rowland JR, Krailo M, et al. Predictive power of pretreatment prognostic factors in children with hepatoblastoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 2009; 53: 1016-1022.
21. De Ioris M, Brugieres L, Zimmermann A, et al. Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: The SIOPEL group experience. Eur J Cancer 2008; 44: 545-550.
22. Meyers RL, Katzenstein HM, Krailo M, et al. Surgical resection of pulmonary metastatic lesions in children with hepatoblastoma. J Pediatr Surg 2007; 42: 2050-2056.